Home › Categories › Science & Nature› Immutep Limited: LAG-3 Therapeutics Update - EGM Presentation (26 July 2021)

Immutep Limited: LAG-3 Therapeutics Update - EGM Presentation (26 July 2021).pdf

44ymxbh7d6x18b.pdf
Preview of Immutep Limited: LAG-3 Therapeutics Update - EGM Presentation (26 July 2021)
🔗 Source: asx.com.au
📊 Size: 1.43 MB
👤 Author: IMM
⬇️ Downloads: 222

Summary

Immutep is a leading biotechnology company focused on developing innovative immunotherapies for cancer and autoimmune disease, with a particular emphasis on LAG-3 (Lymphocyte Activation Gene 3) therapeutics.

Key Points:

Global Leadership in LAG-3: Immutep holds the world's most advanced portfolio of four LAG-3 product candidates, each with distinct mechanisms of action. LAG-3 is a promising immune checkpoint being explored for cancer treatment, with growing interest from the scientific community and pharmaceutical giants like Bristol Myers Squibb.
 Clinical Potential: Immutep's product candidates demonstrate clinical potential in various indications with high unmet needs, including cancer and autoimmune diseases.
Collaboration Deals: The company has established partnerships with industry leaders, strengthening its research and development capabilities.
 Scientific Validation: Extensive scientific literature (over 900 publications) and ongoing clinical trials (involving over 20,000 patients globally) highlight the significance of LAG-3 in cancer treatment. Immutep's anti-LAG-3 antibody has shown promising results in Phase III trials for melanoma, leading to extended progression-free survival.

Conclusion:

Immutep is positioned at the forefront of LAG-3 immunotherapy research and development, leveraging its unique technology platform and strategic partnerships to potentially deliver life-changing treatments for patients with diverse diseases.

Download File

Description

IMMP), global leader in LAG-3 therapeutics, presents an update at its Extraordinary General Meeting on 26 July 2021, highlighting business progress and future prospects. Information is for reference only, subject to further clarification, and should be accompanied by past/future announcements and official filings.

Technical Information

  • File Format: PDF
  • File Size: 1.43 MB
  • Pages: 24
  • Language: EN
  • Author: IMM
  • Total Downloads: 222
  • Last Updated: 2 months ago

Document Overview

This PDF document about Immutep Limited: LAG-3 Therapeutics Update - EGM Presentation (26 July 2021) provides comprehensive information and guidance. Whether you're a beginner or advanced user, this resource offers valuable insights into Immutep Limited: LAG-3 Therapeutics Update - EGM Presentation (26 July 2021).

Related Topics

If you're interested in Immutep Limited: LAG-3 Therapeutics Update - EGM Presentation (26 July 2021), you might also want to explore:

Immutep guideImmutep tutorialLimited: guideLimited: tutorialLAG-3 guideLAG-3 tutorialTherapeutics guideTherapeutics tutorialUpdate guideUpdate tutorialPresentation guidePresentation tutorialJuly guideJuly tutorial2021) guide2021) tutorial

Related Categories

Business & Finance
41204 documents
Education & Learning
22711 documents
Health & Wellness
8956 documents
Technology
4783 documents

Related Documents

Preview of Immutep Limited Updates on LAG-3 Therapeutics
PDF file

Immutep Limited Updates on LAG-3 Therapeutics

2.26 MBIMMEN33 pages
IMMP), global leader in LAG-3 therapeutics, invites you to its Virtual Healthcare Conference from June 1-4, 2021. The presentation offers a business...
Download
Preview of Immutep Limited Business Update Webcast Slides
PDF file

Immutep Limited Business Update Webcast Slides

801 KBMarleen JustinEN13 pages
Immutep Limited presented an update on its business during a webcast on March 26, 2019, at 7:45 AM AEDT/3:45 PM EDT on March 25. The slides,...
Download
Preview of Immutep Limited 2021 Annual General Meeting Dates and Virtual Access Details
PDF file

Immutep Limited 2021 Annual General Meeting Dates and Virtual Access Details

258 KBDeanne MillerEN2 pages
Immutep Limited invites shareholders to its virtual 2021 Annual General Meeting on November 26, 2021, at 10:00 am AEDT. Director nominations for...
Download
Preview of Immutep Share Plan
PDF file

Immutep Share Plan

1.06 MBDeanne MillerEN15 pages
Immutep Limited announced a $60 million two-tranche placement of new shares at A$0.52 per share, with the second tranche conditional on shareholder...
Download
Preview of IMM CEO Update
PDF file

IMM CEO Update

978 KBMarleen JustinEN23 pages
Immutep Limited, a global leader in developing LAG-3 therapeutics, reports strong operational and financial progress, with a focus on LAG-3...
Download

Download Immutep Limited: LAG-3 Therapeutics Update - EGM Presentation (26 July 2021) eBooks for free and learn more about Immutep Limited: LAG-3 Therapeutics Update - EGM Presentation (26 July 2021). These books contain exercises and tutorials to improve your practical skills, at all levels!

Not satisfied with this document? We have related documents to Immutep Limited: LAG-3 Therapeutics Update - EGM Presentation (26 July 2021), try searching with similar keywords: Immutep Limited: LAG-3 Therapeutics Update - EGM Presentation (26 July 2021), Immutep Limited Updates on LAG-3 Therapeutics, Immutep Limited Updates On Lag 3 Therapeutics, Immutep Limited 2021 Annual General Meeting Dates and Virtual Access Details, Immutep Limited: Lapse of Unlisted Options and Remaining Securities Update, Immutep Limited Business Update Webcast Slides, Indexed Contribution Rates - Mackay, Mirani, Sarina - effective 1 July 2021 to 31 July 2021, Appendix 3Y: Director's Interest Change - Grant Chamberlain, IMMUTEP LIMITED

You can download PDF versions of the user's guide, manuals and ebooks about Immutep Limited: LAG-3 Therapeutics Update - EGM Presentation (26 July 2021), you can also find and download for free A free online manual (notices) with beginner and intermediate, Downloads Documentation, You can download PDF files (or DOC and PPT) about Immutep Limited: LAG-3 Therapeutics Update - EGM Presentation (26 July 2021) for free, but please respect copyrighted ebooks.